Just taking a guess on this but its possible the
Post# of 146346
![](/assets/46931549/no_avatar_available_thumb.jpg)
Just taking a guess on this but its possible the FDA needs clarification on m/m regarding protocol and profile of the patients who would receive the shot(s) vs who wouldnt. Will it be based on a NEWS2 profile ? and if so , how many categories need to show a problem? one ? two ? or? there isnt enough leronlimab to give everyone a shot who is infected obviously so there may be some back and forth between the FDA and Cytodyn for clarity, if its not already in the submission
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)